5-bromo-2-chloro-N-[(3R)-oxolan-3-yl]pyrimidin-4-amine | 910780-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-bromo-2-chloro-N-[(3R)-oxolan-3-yl]pyrimidin-4-amine
• CAS: 910780-65-3
• 化学式: C₈H₉BrClN₃O
• 分子量: 278.536
• InChiKey: XWROFZYGXPSGPL-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
  申请人：Luecking Ulrich

  公开号：US20060229325A1

  公开（公告）日：2006-10-12

  This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

  本发明涉及通式（I）的嘧啶衍生物，其中Q，R1，R2，R3，R4，R5，X和m的含义如描述中所含，作为细胞周期蛋白依赖性激酶和VEGF受体酪氨酸激酶的抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。
• N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1861378A1

  公开（公告）日：2007-12-05
• US7456191B2
  申请人：——

  公开号：US7456191B2

  公开（公告）日：2008-11-25
• [EN] N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] PYRIMIDINES SUBSTITUEES PAR LA N-ARYL-SULFOXIMINE COMME INHIBITEURS DE CDK- ET/OU DE VEGF, LEUR PRODUCTION ET LEUR UTILISATION COMME AGENTS PHARMACEUTIQUES
  申请人：SCHERING AG

  公开号：WO2006099974A1

  公开（公告）日：2006-09-28

  [EN] Abstract This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
  [FR] Cette invention concerne des dérivés de la pyrimidine de formule générale (I) dans laquelle Q, R1, R2, R3, R4, R5, X, et m ont les significations qui sont contenues dans la description, comme inhibiteurs des kinases dépendant de la cycline et des tyrosine kinases du récepteur VEGF, leur production de même que leur utilisation comme médicaments pour le traitement de diverses maladies.
• [EN] HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ASTRAZENECA AB

  公开号：WO2010038081A2

  公开（公告）日：2010-04-08

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.